Dao Sen Wang, Amy Phu, Kristen McKee, Simone I Strasser, Sinead Sheils, Martin Weltman, Sue Sellar, Joshua S Davis, Mel Young, Alicia Braund, Geoffrey C Farrell, Anne Blunn, Damian Harding, Lucy Ralton, Kate Muller, Scott A Davison, David Shaw, Marnie Wood, Krispin Hajkowicz, Richard Skolen, Jane Davies, Jaclyn Tate-Baker, Adam Doyle, Rhoda Tuma, Simon Hazeldine, Wendy Lam, Natalie Edmiston, Krista Zohrab, William Pratt, Belinda Watson, Amany Zekry, Carlie Stephens, Paul J Clark, Melany Day, Gordon Park, Hami Kim, Mark Wilson, Bruce McGarity, Natalie Menzies, Darren Russell, Thao Lam, Peter Boyd, Jen Kok, Jacob George, Mark W Douglas
BACKGROUND: Hepatitis C virus (HCV) infection can now be cured with well-tolerated direct-acting antiviral (DAA) therapy. However, a potential barrier to HCV elimination is the emergence of resistance-associated substitutions (RASs) that reduce the efficacy of antiviral drugs, but real-world studies assessing the clinical impact of RASs are limited. Here, an analysis of the impact of RASs on retreatment outcomes for different salvage regimens in patients nationally who failed first-line DAA therapy is reported...
April 2024: Open Forum Infectious Diseases